Ward Jackson Paine, M.D.
Exemplar Research, Inc.
1526 Mileground Road
Morgantown, WV 26505

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 803 7149 (cell)
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

Exemplar Research, Inc.
1325 Locust Avenue
Fairmont, WV 26554

Madison Rehab/Nursing Center
161 Bakers Ridge Road
Morgantown, WV 26505

Golden Living Center
1379 Van Voorhis Road
Morgantown, WV 26505

EDUCATION:

1995 Medical Doctor
West Virginia School of Medicine, Morgantown, WV

1992 Master of Arts, Medical Science
Boston University, Boston, MA

1988 Bachelor of Arts, Biology
Boston University, Boston, MA

INTERNSHIP and RESIDENCY:

1999 Residency Internal Medicine
West Virginia University, Morgantown, WV

CERTIFICATION:

Board Certified in Internal Medicine
GCP Training: CITI
CPR Certified
ACLS Certified

LICENSURE:

2001 West Virginia Medical License # 20635

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2012 – Present
Exemplar Research, Inc., Morgantown, WV

Sub-Investigator, Aug 2010 – 2012
Exemplar Research, Inc., Morgantown, WV

Physician, 2004 – Present
Private Practice, Morgantown, WV

Medical Director, 2004 – Present
Madison Rehab/Nursing Center, Morgantown, WV

Medical Director, 2007 – Present
Golden Living Center, Morgantown, WV

Physician, 2002 – 2006
Morgantown Internal Medicine, Morgantown, WV

Specialist, 2003 – 2008
Wound Healing Center, Morgantown, WV

INVESTIGATOR RESEARCH EXPERIENCE:

Asthma • Chronic Obstructive Pulmonary Disease (COPD) • Complex Regional Pain Syndrome Erythromelalgia • Fibromyalgia • Genitourinary Tuberculosis • Gout • Hypertriglyceridemia Influenza • Irritable Bowel Syndrome • Nocturia • Pain • Renal Function • Women's Health

INVESTIGATOR TREATMENT EXPERIENCE:

Arthritis • Cardiology • Cholesterol • Gastroenterology Hepatic • Infectious Disease Inflammation • Joint Pain • Lyme's Disease • Metabolic • Orphan Diseases • Osteoarthritis Post-Operative Pain • Psoriatic Arthritis • Sinusitis • Ulcerative Colitis

CLINICAL TRIAL EXPERIENCE:

Asthma

A Phase III, 12-week, randomized, double-blind, placebo-controlled, multicenter, parallel group, study evaluating the efficacy and safety of XXX QID compared to XXX QID and XXX QID in adult and adolescent subjects with asthma

A Long-term, Randomized, Double-blind, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of XXX Compared to XXX Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 6 Years of Age or Older with Asthma

A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic XXX and XXX Inhalation Powder Compared with XXX in Subjects with Asthma

A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of XXX to Placebo and Open-label XXX in Subjects With Persistent Asthma

A 6-month Study to Assess the Safety and Benefit of Inhaled XXX Combination Compared with Inhaled XXX in the Treatment of Adolescents and Adults (12 Years of Age and Older) with Asthma

A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of XXX to Placebo and Open-label XXX in Subjects with Persistent Asthma

COPD

A Phase IV Pilot Study in COPD and asthmatic patients to ascertain patient acceptability/ suitability and technological feasibility of data collection by remote monitoring devices

A Clinical Outcomes Study to Compare the Effect of XXX 100/25mcg with Placebo on Survival in Subjects with Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease

A Double Blind, Randomized, Placebo-Controlled, Parallel-group, Phase IV Study to Evaluate the Effect of XXX on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (ASCENT COPD)

A 52 Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of XXX 500ug on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated With Fixed-Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS)

CLINICAL TRIAL EXPERIENCE (*continued*):

Fibromyalgia

An Open -Label Extension Study of XXX for 52 Weeks in Pain Associated with Fibromyalgia

A Randomized, Double-Blind, Placebo- and Active Controlled Study of XXX in Subjects with Pain Associated with Fibromyalgia

Gout

A randomized, double-blind, active-control, multicenter, efficacy and safety study of 2 dose levels of subcutaneous XXX compared to intramuscular XXX in the treatment of acute gouty arthritis, followed by a one-year extension

A Phase III Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of XXX and XXX Compared to XXX Alone in Subjects with Gout who have had an Inadequate Hypouricemic Response to Standard of Care Allopurinol

A Phase III Randomized, Double-Blind, Multi-center, Placebo-Controlled Study to Assess the Efficacy and Safety of XXX Monotherapy Compared to Placebo in Subjects with Gout and Intolerance or Contraindication to the Xanthine Oxidase Inhibitor

A Phase III Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of XXX and XXX Compared to XXX Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects Tophaceous Gout

Irritable Bowel Syndrome

A Double-Blind, Placebo Controlled, Phase II, Responsive Adaptive Randomization Study of XXX in Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)

A Phase II, Multi Center, Randomized, Double Blind, Placebo Controlled Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of XXX in Subjects with Irritable Bowel Syndrome Experiencing Abdominal Pain

A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

CLINICAL TRIAL EXPERIENCE (*continued*):

A Week Double Blind, Randomized, Placebo-Controlled, Parallel Group Phase III Study, Followed by A 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Oral XXX 10 mg Once Daily in Female Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)

A Randomized, Double-blind, Placebo-controlled, Phase III study to Evaluate the Efficacy, Safety, and Tolerability of XXX in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome

Women's Health

A Randomized Double-blind Placebo Controlled Phase III Study to evaluate the Efficacy and Safety of XXX for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (XXX Study I)

A Randomized Double-blind Placebo Controlled Phase III Trial to evaluate the Efficacy and Safety of XXX for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (XXX Study II)

A Randomized, Placebo-Controlled, Double-Blind Phase III Clinical Study to Investigate the Long-Term Safety of XXX in Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated with Menopause

Other Indications

A Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension to Demonstrate the Efficacy and Safety of XXX Orally Disintegrating Tablets for the Treatment of Nocturia in Adult Males.

A Randomized, Double-Blind, Placebo Controlled Study of XXX in Adults and Adolescents with Acute Uncomplicated Influenza.

A Placebo-controlled efficacy and safety trial of intravenous XXX acid in subjects with complex regional pain syndrome (CRPS)

An Exploratory, Randomized, Double-Blind, Crossover Study to Compare the Efficacy and Safety of XXX Versus Placebo in the Treatment of Primary Inherited Erythromelalgia

A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of XXX in Adult Patients With Fasting Triglyceride Levels □500 mg/dL and <2000 mg/dL and Mild or Moderate Renal Impairment

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With a 40-Week, Active-Controlled, Double-Blind Extension to Evaluate the Efficacy and Safety of XXX in Adult Patients With Fasting Triglyceride Levels □500 mg/dL and <2000 mg/dL and Normal Renal Function

Lyme Test Indication Combination (Observational)

PRESENTATIONS:

2001 Presented at West Virginia American College of Physicians Meeting
Case Presentation of Genitourinary Tuberculosis

1991 Boston University
Master's Thesis: Investigated different methods of creating a basic research model for lung cancer. Compared different culture methods of hamster tracheal epithelium. Used electron microscope to compare morphologic criteria to determine the best culture method.